Clinical Trials Browser

Phase 2 × OTHER × Muscle Invasive Bladder Urothelial Carcinoma × Clear all

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT06257017 2025-04-04

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Phase 2 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma